| Year |
Citation |
Score |
| 2017 |
Butt A, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-Samra A. HCV Treatment Initiation in Patients with Chronic Kidney Disease: Results from ERCHIVES Open Forum Infectious Diseases. 4. DOI: 10.1093/Ofid/Ofx163.384 |
0.301 |
|
| 2017 |
Alkadi MM, Ren Y, Puenpatom A, Kumar R, Arduino JM, Abou-Samra A-, Butt AA. Treatment uptake and real world effectiveness of sofosbuvir/ ledipasvir and paritaprevir/ritonavir/ombitasvir/dasabuvir among HCV-infected persons with chronic kidney disease Journal of Hepatology. 66. DOI: 10.1016/S0168-8278(17)31934-7 |
0.305 |
|
| 2017 |
Alkadi M, Ren Y, Abou-Samra A-, Puenpatom A, Arduino JM, Kumar R, Butt AA. Decline in eGFR in HCV-infected patients while on treatment with sofosbuvir/ledipasvir or PrOD regimens is not dependent on baseline eGFR Journal of Hepatology. 66. DOI: 10.1016/S0168-8278(17)31933-5 |
0.306 |
|
| 2017 |
Alkadi M, Ren Y, Puenpatom A, Kumar R, Arduino JM, Abou-Samra A, Butt A. Treatment Uptake and Real World Effectiveness of Sofosbuvir/Ledipasvir and Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Among HCV-Infected Persons with Chronic Kidney Disease Gastroenterology. 152. DOI: 10.1016/S0016-5085(17)33707-1 |
0.305 |
|
| 2013 |
Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (Baltimore, Md.). 57: 2164-70. PMID 23280550 DOI: 10.1002/Hep.26218 |
0.308 |
|
| 2011 |
Chaudhary MA, Elbasha EH, Kumar RN, Nathanson EC. Cost-effectiveness of raltegravir in HIV/AIDS. Expert Review of Pharmacoeconomics & Outcomes Research. 11: 627-39. PMID 22098278 DOI: 10.1586/Erp.11.79 |
0.391 |
|
| 2011 |
Vieira MC, Kumar RN, Jansen JP. Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison. Hiv Clinical Trials. 12: 175-89. PMID 22044854 DOI: 10.1310/Hct1204-175 |
0.318 |
|
| 2011 |
Naik S, Lundberg J, Kumar R, Sjolin J, Jansen JP. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden Scandinavian Journal of Infectious Diseases. 43: 504-514. PMID 21332286 DOI: 10.3109/00365548.2011.556145 |
0.335 |
|
| 2011 |
Wisniewski T, Klimko N, Laverdiere M, Kiertiburanakul S, Kliasova G, Trenschel R, Kumar RN. Retrospective evaluation of caspofungin therapy in invasive aspergillosis (RECAM-IA). Mycoses. 54: e148-53. PMID 20202110 DOI: 10.1111/J.1439-0507.2010.01861.X |
0.308 |
|
| 2011 |
Chaudhary M, Elbasha EH, Kumar RN, Lundberg J. PIN33 COST-UTILITY ANALYSIS OF RALTEGRAVIR IN HIV-INFECTED TREATMENT NAïVE PATIENTS IN SWEDEN Value in Health. 14. DOI: 10.1016/J.Jval.2011.02.664 |
0.367 |
|
| 2010 |
Moore RD, Kumar R. Outcomes of Ritonavir-Boosted Protease Inhibitor Versus Non-Nucleoside Reverse Transcriptase Regimens in a Clinical Practice Cohort Journal of Antivirals & Antiretrovirals. 2: 1-7. DOI: 10.4172/Jaa.1000016 |
0.321 |
|
| 2010 |
Erdesz D, Nagy L, Brandtmuller A, Kiss Z, Chaudhary M, Kumar R, Elbasha E. Pin52 An Economic Evaluation Of Raltegravir For The Treatment Of Antiretroviral-Naive Hiv-1 Infected Patients In Hungary Value in Health. 13. DOI: 10.1016/S1098-3015(11)72850-9 |
0.341 |
|
| 2010 |
Chaudhary M, Elbasha E, Pereira R, Kumar R. Pin34 A Continuous-Time Economic Model To Evaluate Raltegravir Use Strategies In Treatment-Naive Hiv-1 Patients In Portugal Value in Health. 13. DOI: 10.1016/S1098-3015(11)72833-9 |
0.325 |
|
| 2009 |
Jansen JP, Kumar R, Carmeli Y. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value in Health. 12: 234-244. PMID 20667059 DOI: 10.1111/J.1524-4733.2008.00439.X |
0.335 |
|
| 2009 |
Pujari S, Srasuebkul P, Sungkanuparph S, Lim PL, Kumarasamy N, Chuah J, Kumar RN, Chen YM, Oka S, Choi JY, Lee MP, Phanuphak P, Kamarulzaman A, Lee C, Fujie Z, et al. Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region. Journal of Antivirals & Antiretrovirals. 1: 28-35. PMID 20505782 DOI: 10.4172/Jaa.1000004 |
0.325 |
|
| 2009 |
Jansen JP, Kumar R, Carmeli Y. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. Pharmacoeconomics. 27: 1045-1056. PMID 19908928 DOI: 10.2165/11310080-000000000-00000 |
0.343 |
|
| 2009 |
Elbasha EE, Szucs T, Chaudhary MA, Kumar RN, Roediger A, Cook JR, Opravil M. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. Hiv Clinical Trials. 10: 233-53. PMID 19723611 DOI: 10.1310/Hct1004-233 |
0.372 |
|
| 2009 |
Chaudhary MA, Moreno S, Kumar RN, Nocea G, Elbasha E. Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain. Aids Research and Human Retroviruses. 25: 679-89. PMID 19552590 DOI: 10.1089/Aid.2008.0254 |
0.372 |
|
| 2008 |
Stam WB, Aversa F, Kumar RN, Jansen JP. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 11: 830-41. PMID 18494752 DOI: 10.1111/J.1524-4733.2008.00324.X |
0.332 |
|
| 2008 |
Elbasha E, Dunlop W, Chaudhary M, Kumar R. An economic evaluation of using raltegravir in treatment-experienced HIV-1 infected patients in the UK Journal of the International Aids Society. 11: 310. DOI: 10.1186/1758-2652-11-S1-P310 |
0.368 |
|
| 2007 |
Kumar RN, Kirking DM, Hass SL, Vinokur AD, Taylor SD, Atkinson MJ, McKercher PL. The association of consumer expectations, experiences and satisfaction with newly prescribed medications. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 16: 1127-36. PMID 17530445 DOI: 10.1007/S11136-007-9222-4 |
0.525 |
|
| 2007 |
Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, Jansen JP. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. European Journal of Haematology. 78: 532-9. PMID 17419744 DOI: 10.1111/J.1600-0609.2007.00850.X |
0.335 |
|
| 2006 |
Chen CY, Kumar RN, Feng YH, Ho CH, You JY, Liao CC, Tseng CH, Mavros P, Gerth WC, Chen YC. Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan. The Journal of Antimicrobial Chemotherapy. 57: 1181-8. PMID 16595642 DOI: 10.1093/Jac/Dkl107 |
0.332 |
|
| Show low-probability matches. |